Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1
Status:
Completed
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy, safety and tolerability of switching from the older,
established single tablet regimen of ATRIPLA® (EFV/FTC/TDF) to a new single tablet regimen of
BIKTARVY® (BIC/FTC/TAF), in HIV-1 infected adult subjects who are virologically suppressed
(HIV-1 RNA<50 copies/mL).